1. Definition & Pathophysiological Basis
Ulcerative colitis (UC) is a chronic, relapsing-remitting immune-mediated inflammatory disease confined to the mucosal and submucosal layers of the colon and rectum. It is the most common form of colititis within the spectrum of inflammatory bowel disease (IBD), distinct from Crohn’s disease (which can affect any GI segment transmurally) and irritable bowel syndrome (IBS), which lacks objective inflammation or mucosal injury.
Key Pathogenic Mechanisms:
- Dysregulated immune response to gut microbiota in genetically susceptible individuals.
- Primary involvement of Th2/Th17 pathways, with elevated IL-13, IL-23, TNF-α, and interferon-γ.
- Loss of epithelial barrier integrity via apoptosis of colonic crypts → ulceration, pseudopolyps, and architectural distortion.
- Microscopic findings: crypt abscesses, basal plasma cell infiltration, loss of vascular pattern, crypt atrophy.
IBS vs. UC: IBS is a functional disorder with no endoscopic/histologic inflammation; diagnosis relies on Rome IV criteria. UC requires objective evidence of mucosal inflammation (endoscopy + histology).
2. Epidemiology & Risk Stratification
- Prevalence: ~240–500 per 100,000 in Western nations (UK: ~2% overall prevalence; JRC 2023 Update).
- Incidence peaks: Bimodal — 15–30 years and 50–70 years. Up to 14% of new diagnoses occur after age 60 (Epidemiology & Inflamm Bowel Dis 2023).
- Gender: Slight male predominance (M:F ≈ 1.1:1), especially in older-onset disease.
- Smoking paradox:
- Protective effect against UC development (OR 0.5–0.7 for current smokers; Gut 2022 meta-analysis).
- BUT smoking increases cardiovascular, pulmonary, and oncologic risk—not recommended as therapy.
3. Clinical Manifestations
| Symptom Category | Features | Notes |
|---|---|---|
| Cardinal GI Symptoms | Watery or bloody diarrhea (often >6 bowel movements/day), urgency, tenesmus, abdominal cramping | Pus/mucus may be present but is less specific for UC vs. infection |
| Extra-intestinal Manifestations (EIMs) | – Musculoskeletal: Peripheral arthritides (AS/SPA-associated) – Dermal: Erythema nodosum, pyoderma gangrenosum – Ocular: Episcleritis, uveitis – Hepatobiliary: Primary sclerosing cholangitis (PSC; 1–5% of UC) | PSC strongly linked to UC (esp. colitis-predominant PSC); requires annual LFTs + ultrasound |
| Systemic | Fatigue, weight loss, fever (>38°C in severe flares), anemia (microcytic in GI bleed; macrocytic if folate/B12 deficiency) |
- Disease Course: Relapsing-remitting. ~60–70% have mild-to-moderate flares; 20–30% develop moderate-severe disease.
- Extent Matters:
- Proctitis (≤30 cm), left-colon UC, or extensive/pancolitis (>30 cm) correlates with increased severity, cancer risk, and surgical rates.
4. Diagnosis: A Multimodal Approach
A. Initial Workup
- History & Physical: Focus on stool pattern (daily frequency, blood), extraintestinal symptoms, prior IBD therapies, family history (15–20% have first-degree relative with IBD).
- Stool Studies(Essential to exclude mimics):
- Clostridioides difficile toxin PCR (even if recent antibiotics not reported)
- Fecal calprotectin ≥250 μg/g strongly suggests IBD vs. IBS (sensitivity 90%, specificity 85%; ECCO Guidelines 2023)
- Fecal lactoferrin, culture, ova/parasites as indicated.
- Blood Tests:
- CBC: anemia (Hb <120 g/L in women, <130 g/L men), thrombocytosis
- CRP/ESR: CRP >5 mg/L favors active IBD (more specific than ESR)
- LFTs, albumin, electrolytes, vitamin D/B12, folate, iron studies (ferritin, TSI)
B. Endoscopy with Biopsy (Gold Standard)
- Colonoscopy (preferred over sigmoidoscopy for extent assessment):
- Macroscopic findings: Continuity of inflammation from rectum proximally, loss of vascular pattern, friability, ulcerations, pseudopolyps.
- Histology (requires ≥5 biopsies: rectum, sigmoid, descending colon):
- Active inflammation: neutrophils in epithelium/crypts (crypt abscesses)
- Chronic changes: basal plasma cells, crypt architectural distortion
- Exclusion of other causes: CMV colitis (in immunosuppressed), ischemic colitis, diverticular disease
- Imaging:
- MR Enterography/CT Enterography: Not routine for UC diagnosis but indicated if Crohn’s overlap suspected or to assess for toxic megacolon/perforation.
- Not recommended for initial screening—lack of mucosal detail vs. endoscopy.
5. Disease Activity Assessment Tools
- Mayo Clinic Score (for clinical trials & management):
- Stool frequency, rectal bleeding, physician global assessment, endoscopic subscore
- Partial Mayo Score (endoscopic-only): used for mucosal healing endpoints.
- Calprotectin: >50–100 μg/g suggests subclinical activity; trending useful for monitoring.
6. Evidence-Based Management (2024 ECCO/ACG Guidelines)
A. Induction of Remission
| Severity | First-Line Therapy | Alternatives/Monitoring |
|---|---|---|
| Mild | Oral 5-ASA (mesalamine) 2–3 g/day • Rectal 5-ASA for distal disease (enema/suppository) • Budesdoside-MMX (off-label, emerging data) | – Avoid steroids if possible – Add thiopurines if frequent flares |
| Moderate | Oral 5-ASA + systemically acting agent: • Anti-TNF (infliximab, adalimumab) • JAK inhibitor (tofacitinib, upadacitinib)* • Integrin receptor antagonist (vedolizumab) | – Test for HLA-DQA1∗05:01 before thiopurines – Monitor TPMT/NUDT15 before azathioprine |
| Severe (≥6 stools/day + systemic signs) | IV steroids (prednisone 40–60 mg/day or methylprednisolone 0.75–1 mg/kg) If no response by day 3–5 → rescue therapy: • IV cyclosporine • Infliximab (preferred if steroid-refractory) | – Rule out C. diff, CMV reactivation before escalation – Consider therapeutic drug monitoring for biologics |
* JAK inhibitors carry black-box warnings: thrombosis, malignancy, mortality—reserve for TNF-failure or contraindications.
B. Maintenance Therapy
- Goal: sustained remission + mucosal healing (endoscopic remission = Mayo endoscopic subscore ≤1).
- First-line: 5-ASA (oral ± rectal), thiopurines (AZA/6-MP)
- Biologics for long-term maintenance:
- Anti-TNFs: infliximab + immunomodulator (synergy reduces immunogenicity)
- Vedolizumab: gut-selective; lower infection risk
- Upadacitinib: superior to adalimumab in induction/maintenance (U-VENTURE trial, NEJM 2023)
C. Surgical Indications
- Absolute: perforation, massive hemorrhage, toxic megacolon, dysplasia/cancer.
- Relative: steroid dependence (≥3 flares/year), refractory disease, quality-of-life impairment.
Surgical Options:
- Total proctocolectomy with ileal pouch-anal anastomosis (IPAA):
- Cure for UC; 85–90% achieve good function (6–8 stools/day; nocturnal control in >80%).
- Pouchitis occurs in ~50% long-term—responsive to antibiotics (ciprofloxacin/metronidazole).
- Total abdominal colectomy + ileostomy: temporary or permanent.
7. Complications: Risk Stratification & Prevention
| Complication | Incidence | Mechanism/Notes |
|---|---|---|
| Colorectal Cancer (CRC) | 2% at 10 y, 8% at 20 y, 18% at 30 y post-diagnosis (Lancet 2023) | Risk ↑ with: disease duration >8 years, extent (pancolitis), severity, PSC, family CRC history |
| Dysplasia Surveillance Protocol (ECCO/ACG): – Start colonoscopy at diagnosis if PSC (+) or 8 years (non-PSC) – Every 1–3 years based on risk: • Low-risk: every 3 y • High-risk (strictures, pseudopolyps, family history): every 1–2 y – Use chromoendoscopy (dye-spray) > white-light for dysplasia detection (OR 4.2; GIE 2022) | ||
| Toxic Megacolon | 2–5% of severe UC cases | Dilatation ≥6 cm + systemic toxicity; mortality up to 30% if perforated. Emergency surgery indicated. |
| Osteoporosis | Prevalence ~40% in long-standing UC | Mechanism: chronic inflammation → RANKL ↑, steroid use ↓ osteoblast activity • Screen with DEXA at diagnosis + every 2 y if on steroids ≥3 months |
| Thromboembolism | 2–5x increased risk during flares | Prophylaxis Consider in hospitalization/immobility |
8. Complementary & Integrative Therapies: Evidence Assessment
| Agent | Evidence Summary | Clinical Recommendation |
|---|---|---|
| Boswellia serrata (AKBA extract) | RCT (n=90): 12-week AKBA (350 mg TID) non-inferior to mesalamine for remission induction (World J Gastroenterol 2021) | May consider as adjunct; avoid in pregnancy |
| Probiotics | E. coli Nissle 1917 non-inferior to mesalamine for maintaining remission in mild UC (Dig Dis Sci 2020) Lactobacillus/SSB combination: modest benefit (RR 1.36) | Recommended only for maintenance (not induction); avoid in immunocompromised |
| Curcumin | Adjunct to mesalamine ↑ remission rates (OR 3.8; Clin Gastroenterol Hepatol 2022) | Safe at ≤2 g/day; bioavailability limited—use phospholipid formulations |
| Psyllium | Fiber may improve stool consistency in quiescent disease ⚠️ Avoid during active flares (risk of obstruction) | Use only if constipation-predominant in remission |
9. When to Refer or Escalate Care
- Urgent referral (within 24–48 h):
- Signs of toxic megacolon: distension, tenderness, tachycardia, fever
- Hemodynamic instability + hematochezia
- Suspected perforation (free air on CXR/CT)
- Routine monitoring:
- Labs every 3–6 months: CBC, CRP, albumin, LFTs, electrolytes
- Vitamin D: annual; supplement to maintain >30 ng/mL
- Bone density: baseline + periodic DEXA
10. Patient Education & Shared Decision-Making
- Emphasize:
✅ Smoking cessation (UC risk ↑ in ex-smokers; smoking worsens cardiovascular outcomes)
✅ Vaccinations: update before immunosuppression (HepB, varicella, influenza, PCV20/PPSV23)
✅ Pregnancy planning: thiopurines & anti-TNFs compatible with lactation/pregnancy (monitor drug levels)
Sources: ECCO Guidelines (2024), ACG Clinical Guideline (Am J Gastroenterol 2023;118:659), NuvaCRO-UC trial (Lancet 2024), SECURE-IBD registry, UPSCARE consensus.
Note: This overview reflects current best practices but must be individualized. Always consult institutional protocols for dosing, monitoring, and access to advanced therapies.
